Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ShangPharma Plans to Merge CRO/CMO Operations with Public Entity

publication date: Mar 24, 2017
ShangPharma will combine all of its CRO/CMO operations under the ChemPartner name and merge the entity, sometime in the future, with a public company. The merger will list the CRO/CMO operations on either the Shanghai or Shenzhen exchange. ShangPharma did not disclose whether ShangPharma intends to be the surviving company. However, ShangPharma is holding back at least two of its divisions from ChemPartner: ShangPharma Technologies, which enables new technologies, and ShangPharma Investments, which invests in new drug therapies. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital